Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | PPIA | P62937 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522806 | 0.95 | L3MBTL1 (0.55) | L3MBTL1PPIATSHRRAB9ACASP3 | |
| SCHEMBL3516526 | 0.90 | L3MBTL1 (0.55) | L3MBTL1PPIATSHRRAB9ACASP3 | |
| SCHEMBL3519261 | 0.87 | L3MBTL1 (0.54) | L3MBTL1PPIATSHRRAB9ACASP3 | |
| SCHEMBL16236493 | 0.84 | NPSR1 (0.43) | L3MBTL1PPIATSHRRAB9AALDH1A1 | |
| SCHEMBL17181733 | 0.83 | MAPT (0.45) | L3MBTL1PPIAALDH1A1HTTMAPT | |
| SCHEMBL1522651 | 0.78 | HSD17B10 (0.46) | L3MBTL1TSHRRAB9AALDH1A1HTT | |
| SCHEMBL3515081 | 0.78 | L3MBTL1 (0.42) | L3MBTL1PPIATSHRRAB9ACASP3 | |
| SCHEMBL15846420 | 0.78 | TSHR (0.48) | L3MBTL1PPIATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3517908 | 0.76 | LMNA (0.41) | L3MBTL1RAB9AALDH1A1HTTMAPT | |
| SCHEMBL16236568 | 0.76 | MAPK1 (0.38) | L3MBTL1ALDH1A1SMN1; SMN2POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-10-26 | — | — | US | disclosed |
| US-9676771-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2996691-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014186398-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | CCR8, CDK8, CHD8 | L3MBTL1 592/4885PPIA 4300/4885TSHR 310/4885 |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | L3MBTL1 592/4885PPIA 4300/4885TSHR 310/4885 |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | L3MBTL1 592/4885PPIA 4300/4885TSHR 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.